Add to ORKGBlinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell transplantation, a feature which it was post allogeneic bone marrow transplantation, a feature which this drug was not aimed to do
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell prec...
Acute lymphoblastic leukemia is by far the most common malignancy in children, and new immunotherape...
International audiencePatients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukem...
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hema...
A woman in her forties with relapsed B-cell lymphoblastic lymphoma was treated with blinatumomab, bu...
lmmunotherapy is an alternative treatment modality for poor conditions associated with chemoresistan...
We report on posttransplant relapsed pediatric patients with B-precursor acute lymphoblastic leukemi...
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (all...
Despite the progress that has been made in recent decades in the treatment of pediatric acute leukem...
Despite the progress that has been made in recent decades in the treatment of pediatric acute leukem...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in a...
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymp...
BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (A...
In summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Cli...
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell prec...
Acute lymphoblastic leukemia is by far the most common malignancy in children, and new immunotherape...
International audiencePatients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukem...
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hema...
A woman in her forties with relapsed B-cell lymphoblastic lymphoma was treated with blinatumomab, bu...
lmmunotherapy is an alternative treatment modality for poor conditions associated with chemoresistan...
We report on posttransplant relapsed pediatric patients with B-precursor acute lymphoblastic leukemi...
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (all...
Despite the progress that has been made in recent decades in the treatment of pediatric acute leukem...
Despite the progress that has been made in recent decades in the treatment of pediatric acute leukem...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in a...
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymp...
BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (A...
In summary, we show rapid and deep remission induced by blinatumomab in CD19(+) blast phase CML. Cli...
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell prec...
Acute lymphoblastic leukemia is by far the most common malignancy in children, and new immunotherape...
International audiencePatients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukem...